Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 1471 AL 1485

Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease

Pati S, Singh Gautam A, Dey M, Tiwari A, Kumar Singh R.

Drug Discov Today. 2023 Dec;28(12):103750. doi: 10.1016/j.drudis.2023.103750. Epub 2023 Aug 24.

Unleashing the Power of Bayesian Re-Analysis: Enhancing Insights into Lecanemab (Clarity AD) Phase III Trial Through Informed t-Test

Costa T, Premi E, Liloia D, Cauda F, Manuello J.

J Alzheimers Dis. 2023;95(3):1059-1065. doi: 10.3233/JAD-230589.

Management of neuropsychiatric symptoms in dementia

Devanand DP.

Curr Opin Neurol. 2023 Oct 1;36(5):498-503. doi: 10.1097/WCO.0000000000001199. Epub 2023 Aug 7.

Semorinemab in Mild-to-Moderate Alzheimer Disease: A Glimmer of Hope Though Cautions Remain

Edland SD, Llibre-Guerra JJ.

Neurology. 2023 Oct 3;101(14):593-594. doi: 10.1212/WNL.0000000000207861. Epub 2023 Aug 29.

Exploring the therapeutic potential of natural compounds for Alzheimer's disease: Mechanisms of action and pharmacological properties

Liu J, Li T, Zhong G, Pan Y, Gao M, Su S, Liang Y, Ma C, Liu Y, Wang Q, Shi Q.

Biomed Pharmacother. 2023 Oct;166:115406. doi: 10.1016/j.biopha.2023.115406. Epub 2023 Sep 4.

Therapeutic targeting of microtubule affinity-regulating kinase 4 in cancer and neurodegenerative diseases

Alam M, Ahmed S, Abid M, Hasan GM, Islam A, Hassan MI.

J Cell Biochem. 2023 Sep;124(9):1223-1240. doi: 10.1002/jcb.30468. Epub 2023 Sep 3.

Berberine derivatives as inhibitors of acetylcholinesterase: A systematic review

Singh YP, Kumar H.

Chem Biol Drug Des. 2023 Dec;102(6):1592-1603. doi: 10.1111/cbdd.14337. Epub 2023 Sep 4.

Tryptamine: A privileged scaffold for the management of Alzheimer's disease

Singh YP, Kumar H.

Drug Dev Res. 2023 Dec;84(8):1578-1594. doi: 10.1002/ddr.22111. Epub 2023 Sep 7.

Guilingji capsule for Alzheimer's disease: secondary analysis of a randomized non-inferiority controlled trial

Ming Z, Yimiao L, Huichan W, Yu C, Lina MA, Hui P, Hao LI.

J Tradit Chin Med. 2023 Oct;43(5):1019-1025. doi: 10.19852/j.cnki.jtcm.20230404.006.

Pathogenesis of Alzheimer's Disease and Diversity of 1,2,3-Triazole Scaffold in Drug Development: Design Strategies, Structural Insights, and Therapeutic Potential

Singh A, Singh K, Kaur J, Kaur R, Sharma A, Kaur J, Kaur U, Chadha R, Bedi PMS.

ACS Chem Neurosci. 2023 Sep 20;14(18):3291-3317. doi: 10.1021/acschemneuro.3c00393. Epub 2023 Sep 8.

Advances in Alzheimer's Disease-Associated Aβ Therapy Based on Peptide

Wang C, Shao S, Li N, Zhang Z, Zhang H, Liu B.

Int J Mol Sci. 2023 Aug 23;24(17):13110. doi: 10.3390/ijms241713110.

Carbamate as a potential anti-Alzheimer's pharmacophore: A review

Singh YP, Kumar N, Chauhan BS, Garg P.

Drug Dev Res. 2023 Dec;84(8):1624-1651. doi: 10.1002/ddr.22113. Epub 2023 Sep 11.

A Randomized Double-blind Study to Assess the Skin Irritation and Sensitization Potential of a Once-weekly Donepezil Transdermal Delivery System in Healthy Volunteers

Sabbagh MN, Mathew P, Blau A.

Alzheimer Dis Assoc Disord. 2023 Oct-Dec 01;37(4):290-295. doi: 10.1097/WAD.0000000000000578. Epub 2023 Sep 11.

Interventions for Care Partners of People With Alzheimer's Disease or Other Related Neurological Conditions to Address Depression (2018-2022)

Rhodus EK, Henley L, Green M, Metzger L, Smallfield S.

Am J Occup Ther. 2023 Mar 1;77(Suppl 1):7710393270. doi: 10.5014/ajot.2023.77S10027.

Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood

Bourdakou MM, Fernández-Ginés R, Cuadrado A, Spyrou GM.

Redox Biol. 2023 Nov;67:102881. doi: 10.1016/j.redox.2023.102881. Epub 2023 Sep 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias